Eisai Licenses Tasurgratinib to SciClone in Greater China Region

Eisai Co., Ltd. has entered into a license agreement granting the exclusive development and distribution rights for the fibroblast growth factor (FGF) receptor selective tyrosine kinase inhibitor tasurgratinib succinate TASFYGO, (tasurgratinib) to a subsidiary of SciClone Pharmaceuticals, in the Greater China region. Eisai will maintain the rights to tasurgratinib worldwide outside of the licensed regions and continue to manufacture and market it in Japan, where it has been already launched.

Under the agreement, Eisai will receive a contractual upfront payment. Additionally, Eisai will receive milestone payments based on the progress of development and regulatory approval, as well as sales milestones and certain royalties.

Tasurgratinib is an orally available novel tyrosine kinase inhibitor that demonstrates selective inhibitory activity against FGFR1, FGFR2 and FGFR3. Tasurgratinib was approved in Japan for the treatment of patients with unresectable biliary tract cancer with FGFR2 gene fusions or rearrangements that progressed after cancer chemotherapy. The medicine was launched in Japan in November 2024. A Phase I clinical trial is underway in Japan for estrogen receptor-positive and HER2-negative breast cancer.

SciClone is a global biopharmaceutical company with an integrated platform for the development and commercialization of therapies for cancer and severe infection, and a strong presence in the Greater China region.